TABLE 1. Estimated vaccination coverage among children aged 19–35 months, by selected vaccines and doses — National Immunization Survey-Child, United States, 2013–2017*.
| Vaccine/Dose | Survey year
% (95% CI) |
||||
|---|---|---|---|---|---|
| 2013 | 2014 | 2015 | 2016 | 2017 | |
|
DTaP†
| |||||
| ≥3 doses |
94.1 (93.2–95.0) |
94.7 (94.0–95.4) |
95.0 (94.4–95.5) |
93.7 (92.8–94.5)§ |
94.0 (93.3–94.7) |
| ≥4 doses |
83.1 (81.8–84.3) |
84.2 (83.0–85.4) |
84.6 (83.5–85.7) |
83.4 (82.1–84.6) |
83.2 (82.0–84.3) |
|
Poliovirus (≥3 doses)
|
92.7 (91.6–93.6) |
93.3 (92.5–94.1) |
93.7 (93.0–94.3) |
91.9 (90.9–92.9)§ |
92.7 (91.9–93.5) |
|
MMR (≥1 dose)¶
|
91.9 (90.9–92.7) |
91.5 (90.6–92.4) |
91.9 (91.0–92.7) |
91.1 (90.1–92.0) |
91.5 (90.6–92.3) |
|
Hib
| |||||
| Primary series** |
93.7 (92.7–94.5) |
93.3 (92.5–94.1) |
94.3 (93.7–94.9) |
92.8 (91.8–93.6)§ |
92.8 (91.9–93.6) |
| Full series** |
82.0 (80.7–83.3) |
82.0 (80.7–83.2) |
82.7 (81.5–83.8) |
81.8 (80.5–83.0) |
80.7 (79.4–82.0) |
|
HepB
| |||||
| ≥3 doses |
90.8 (89.7–91.7) |
91.6 (90.7–92.4) |
92.6 (91.9–93.3) |
90.5 (89.3–91.5)§ |
91.4 (90.5–92.3) |
| Birth dose†† |
74.2 (72.8–75.7)§ |
72.4 (70.9–73.9) |
72.4 (71.0–73.7) |
71.1 (69.5–72.7) |
73.6 (72.0–75.2)§ |
|
Varicella (≥1 dose)¶
|
91.2 (90.2–92.1) |
91.0 (90.1–91.9) |
91.8 (91.0–92.5) |
90.6 (89.6–91.5) |
91.0 (90.1–91.8) |
|
PCV
| |||||
| ≥3 doses |
92.4 (91.4–93.3) |
92.6 (91.8–93.4) |
93.3 (92.5–94.0) |
91.8 (90.8–92.7)§ |
91.9 (90.9–92.8) |
| ≥4 doses |
82.0 (80.6–83.3) |
82.9 (81.6–84.2) |
84.1 (83.0–85.2) |
81.8 (80.4–83.1)§ |
82.4 (81.1–83.6) |
|
HepA
| |||||
| ≥1 dose |
83.1 (81.9–84.3)§ |
85.1 (84.0–86.2)§ |
85.8 (84.7–86.8) |
86.1 (84.9–87.2) |
86.0 (84.8–87.1) |
| ≥2 doses§§ |
54.7 (53.1–56.3) |
57.5 (55.9–59.1)§ |
59.6 (58.1–61.0) |
60.6 (59.1–62.2) |
59.7 (58.2–61.3) |
|
Rotavirus¶¶
|
72.6 (71.1–74.0)§ |
71.7 (70.1–73.2) |
73.2 (71.8–74.6) |
74.1 (72.6–75.5) |
73.2 (71.6–74.7) |
|
Combined 7-vaccine series***
|
70.4 (68.8–71.9) |
71.6 (70.2–73.1) |
72.2 (70.9–73.6) |
70.7 (69.2–72.2) |
70.4 (68.9–71.9) |
| No vaccinations | 0.7 (0.5–1.1) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | 0.8 (0.6–1.0) | 1.1 (0.9–1.4)§ |
Abbreviations: CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = Haemophilus influenzae type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.
* For 2013, children born during January 2010–May 2012; for 2014, children born during January 2011–May 2013; for 2015, children born during January 2012–May 2014; for 2016, children born during January 2013–May 2015; and for 2017, children born during January 2014–May 2016.
† Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.
§ Statistically significant (p<0.05) change in coverage compared with previous survey year.
¶ Includes children who might have been vaccinated with measles, mumps, rubella, and varicella vaccine.
** Hib primary series: ≥2 or ≥3 doses, depending on product type received; full series includes primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.
†† One dose of HepB administered from birth through age 3 days.
§§ Estimates of ≥2 doses of HepA are likely underestimates because a child could be on schedule but not receive a second dose of HepA until age 41 months. This dose would not be collected by NIS-Child, which includes children aged 19–35 months only.
¶¶ Includes ≥2 doses of Rotarix monovalent rotavirus vaccine (RV1), or ≥3 doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.
*** The combined 7-vaccine series (4:3:1:3*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.